To further characterize the systemic toxicity, we selected 3M-052(telratolimod), which is a lipid-modified TLR7/8 agonist designedto form depots for controlled release from the injection site (orfor incorporation into liposomes or cell membranes), as a benchmarkfor TLR7 agonist-induced inflammation.48 We intratumorally injected MC38 colon carcinoma-bearing mice witheither p(Man-TLR7-PDS) or 3M-052 on a TLR7 equimolar basis and evaluatedthe production of systemic inflammatory cytokines. Here, TLR7 is linked to colon carcinoma.